CTx is now seeking projects from research organisations across Australia. One of the first confirmed projects is to find and develop substances directed against BNO69, a proprietary cancer focus on of CTx participant, Bionomics Ltd. Dr Julian Clark, CEO of CTx, stated: The scarcity of intellectual and monetary capital for the fundamental part of the drug discovery process between the laboratory bench and the medical drug development procedure is Australia’s great financing gap. CTx shall offer an integrated and coherent pathway for drug discovery, commercialisation and clinical advancement. CTx will benefit enormously from the experience and track-record of CRT. Our long-term goal is to develop a comparable commercialisation and development company for cancer therapeutics in Australia.Related StoriesDiagnosing traumatic human brain injury through a bloodstream check: an interview with Dr KorleyCharles Bonnet syndrome: an interview with Dr. Dominic do we rest ffytcheWhy? An interview with Professor WisdenOn examination, they found that the animals with trimmed whiskers experienced modified axons, nerve fibers along which details is conveyed in one neuron to numerous others; those whose whiskers weren’t trimmed had no axonal adjustments. Their findings were especially striking as the rats were considered fairly old – meaning that this rewiring can still take place at an age not previously thought possible.